<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614480</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02135-52</org_study_id>
    <nct_id>NCT04614480</nct_id>
  </id_info>
  <brief_title>Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine</brief_title>
  <acronym>EXOMA2</acronym>
  <official_title>A Multicenter, Prospective, Multi-organ Study to Evaluate the Clinical Benefit of an Exome &quot;Complex&quot; Analysis Versus an Exome &quot;Simple&quot; Analysis to Help the Therapeutic Decision for the Precision Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;simple&quot; analysis of the exome can determine somatic and constitutional mutations. The&#xD;
      major challenge lies in the translation of sequencing data into clinically relevant&#xD;
      information allowing the clinician to guide his decision-making A &quot;complex&quot; analysis of the&#xD;
      exome would provide access to structural DNA data, concerning mutational signatures, tumor&#xD;
      mutational load, analysis of large deletions, loss of heterozygosity as well as amplification&#xD;
      of certain genes which may have an impact on the management of patients.&#xD;
&#xD;
      No data available to date makes it possible to assess the clinical interest of the&#xD;
      availability of its additional information resulting from a &quot;complex&quot; analysis compared to a&#xD;
      &quot;simple&quot; analysis. The objective of the EXOMA2 study is to assess the proportion of patients&#xD;
      for whom the proposed therapy is derived from its additional information (complex analysis)&#xD;
      and would not have been possible with a classic exome analysis (simple analysis) .&#xD;
&#xD;
      We hereby formulate the hypothesis that a &quot;complex&quot; analysis on a population presenting a&#xD;
      metastatic or locally advanced disease treated early (from the 1st line of treatment) will&#xD;
      make it possible to determine therapeutic indications which could not be discovered with a&#xD;
      &quot;simple&quot; analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients for whom therapy was initiated from informations of the &quot;complex&quot; exome analysis</measure>
    <time_frame>inclusion</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1392</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient in 1st or 2nd line of treatment for metastatic or locally advanced disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. Weight&gt; 30 Kg&#xD;
&#xD;
          3. Histological or cytological evidence of the diagnosis of a metastatic or locally&#xD;
             advanced solid tumor&#xD;
&#xD;
          4. Patient in 1st or 2nd line of treatment for metastatic or locally advanced disease&#xD;
&#xD;
          5. Tumor material available in sufficient and usable quantity for the analyzes required&#xD;
             by the study&#xD;
&#xD;
          6. Request for exome analysis to be carried out when initiating the 1st or 2nd line of&#xD;
             treatment (line initiated at the time of inclusion)&#xD;
&#xD;
          7. Life expectancy estimated to be probably ≥ 6 months.&#xD;
&#xD;
          8. WHO ≤ 1&#xD;
&#xD;
          9. Normal biological parameters&#xD;
&#xD;
         10. Patient capable and willing to follow all study procedures in accordance with the&#xD;
             protocol&#xD;
&#xD;
         11. Patient having understood the purpose, risks and constraints of the study and having&#xD;
             signed and dated the consent form&#xD;
&#xD;
         12. Patient affiliated to the social security scheme.&#xD;
&#xD;
             Criterion making it possible to definitively validate the inclusion (inclusion in two&#xD;
             stages):&#xD;
&#xD;
         13. Samples (tumor + blood) received by the CGFL within 15 days of signing the consent&#xD;
             with sufficient quantity and quality to perform the exoma analysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumor material not available or biopsy not possible.&#xD;
&#xD;
          2. Inability to take a blood test.&#xD;
&#xD;
          3. Refusal of genetic analysis.&#xD;
&#xD;
          4. Patient likely to progress within 3 months of inclusion in the study.&#xD;
&#xD;
          5. History of HIV / HBV / HCV infection.&#xD;
&#xD;
          6. Patient already included in the EXOMA or EXOMA2 study.&#xD;
&#xD;
          7. Woman who is pregnant, may be, or is breastfeeding.&#xD;
&#xD;
          8. Persons deprived of their liberty or under guardianship (including curatorship).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Coutant, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>Centre Georges François Leclerc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Ghiringhelli, PU-PH</last_name>
    <phone>+33(0)3 80 73 75 00</phone>
    <email>FGhiringhelli@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Rederstorff, PhD</last_name>
    <phone>+33(0)3 80 73 75 00</phone>
    <phone_ext>34 61</phone_ext>
    <email>ERederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno CHAUFFERT, MD</last_name>
      <phone>03 22 45 54 99</phone>
      <email>chauffert.bruno@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura MANSI, MD</last_name>
      <phone>03 70 63 24 03</phone>
      <email>mansi.laura@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO, MD</last_name>
      <phone>05 56 33 33 33</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CGFL</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Rederstorff, PhD</last_name>
      <phone>+33(0)3 80 73 75 00</phone>
      <phone_ext>34 61</phone_ext>
      <email>ERederstorff@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU François Mitterrand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine DROUILLARD, MD</last_name>
      <phone>03 80 29 37 50</phone>
      <email>antoine.drouillard@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois-perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
      <phone>01 47 59 18 73</phone>
      <email>benoist.chibaudel@ihfb.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas PENEL, MD</last_name>
      <phone>03 20 29 59 59</phone>
      <email>n-penel@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaafar BENNOUNA, MD</last_name>
      <phone>02 40 16 59 30</phone>
      <email>jaafar.bennouna@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Isanbert, MD</last_name>
      <phone>05 49 44 45 38</phone>
      <email>nicolas.isambert@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genetic</keyword>
  <keyword>exome</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

